New Partnership Forms to Develop Breakthrough Neuromodulation Device

WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device. The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic brain injury. The condition results in certain muscles continuously contracting, resulting in an interference with normal movement, speech, and gait. Nader Yaghoubi, president and CEO of Pathmaker, says that the new technology was one of the first devices selected under the Expedited Access Pathway (EAP) program from FDA, a program intended for breakthrough medical devices. “The device is based on Pathmaker’s proprietary DoubleStim technology, which provides non-invasive stimulation simultaneously at spinal and peripheral sites associated with the targeted muscle,” he says. “This results in suppression of hyperexcitable spinal circuits found in patients with spasticity. The device is intended to be administered by a medical professional in a clinical setting, and treatments last 20 minu...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news